Document is current
Any future updates will be listed below
-
Authors
Bond, Danielle R. https://orcid.org/0000-0002-5967-0258
Burnard, Sean M. https://orcid.org/0000-0003-2149-3556
Uddipto, Kumar
Hunt, Kooper V.
Harvey, Brooke M.
Steffens Reinhardt, Luiza
Lawlor-O’Neill, Charley
Roper, Ellise A.
Humphries, Sam
Murray, Heather C. https://orcid.org/0000-0001-8953-3708
Mannan, Abdul
Dun, Matthew D. https://orcid.org/0000-0002-9063-5370
de Bock, Charles E. https://orcid.org/0000-0001-5182-8535
Bowden, Nikola A. https://orcid.org/0000-0002-6047-1694
Enjeti, Anoop K. https://orcid.org/0000-0001-8069-090X
Verrills, Nicole M. https://orcid.org/0000-0002-7894-0137
Riveros, Carlos https://orcid.org/0000-0002-2551-7618
Lê Cao, Kim-Anh
Lee, Heather J. https://orcid.org/0000-0002-6482-0337
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (GNT1143614, GNT1180782, GNT2016283, GNT1173892, GNT1180782)
Department of Education and Training | Australian Research Council (DP200102903)
Cancer Institute NSW (2018/ECF001, ECF1299)
Cure Cancer Australia Foundation (CCAF2023-Bond)
Hunter Medical Research Institute (HMRI778)
- License Information
-
More Information
Article History
Received: 10 February 2025
Revised: 16 June 2025
Accepted: 3 July 2025
First Online: 17 July 2025
Competing interests
: AKE declares the following competing interests: advisory board and honoraria from AbbVie, Astellas, Gilead, Servier, Jazz, Otsuka/Astex, and RACE Oncology; speaker fees from AbbVie, Otsuka/Astex, Astellas and Jazz; Research Funding from RACE oncology and Otsuka/Astex. NAB receives research funding from Merck KGaA and Bristol Myers Squibb.
: All experimental procedures using animals were reviewed, approved, and performed according to the Animal Care and Ethics Committee of the University of Newcastle (approval number: A-2023-303), and with consideration of the ARRIVE guidelines (Supplementary Information).
